2020 Clinical Trials Data DEA 
The Cannigma
JUNE 14, 2021
All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinical trials’. BRC) told The Cannigma this week.
Veriheal
AUGUST 31, 2020
It brings us great pleasure to present the 10 winners of Veriheal’s Innovation in Cannabis Scholarship 2020. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” . Nishtha Tripathi. School: George Washington University.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 29, 2022
In 2020, Oregon became the first locale to decriminalize psilocybin and legalize it for therapeutic use on a statewide basis. 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Clinical Trials and Human Subject Protections. DEA and the Controlled Substances Act.
Cannabis Law Report
DECEMBER 21, 2021
It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. Also in November, it reported positive data on its standout IND, CYB003. In 2021 it filed several additional patent applications while conducting head-to-head studies on its lead clinical candidate, MSP-1014.
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,
Expert insights. Personalized for you.
133 
Let's personalize your content